HIMSS Middle East Conference & Exhibition 2013

Global Hospital & Healthcare Management

 

 

 

Monday
May 20th
  • Bookmark and Share
  • Login
  • Sign up
    Registration
    Fields marked with an asterisk (*) are required.
    Name: *
    Username: *
    E-mail: *
    Password: *
    Verify Password: *
    Company name: *
    Position:
    Telephone:
  • Search
Text size
  • Increase font size
  • Default font size
  • Decrease font size
Featured Articles
  • Pause
  • Previous
  • Next
1/15
 
Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis (20.05.2013)
Whole-cell pertussis vaccines were more effective at protecting against pertussis than acellular pertussis vaccines during a large recent outbreak, according to a new Kaiser Permanente study published in Pediatrics.

Whole-cell pertussis vaccines, also called DTwP, were available from the 1940s to 1990s, but were associated with safety concerns that ultimately led to the development of acellular pertussis vaccines, which are also called DTaP. By the late 1990s, the United States had switched from whole-cell to acellular vaccines for all five recommended infant and childhood doses.
 
The study, which followed the 2010-2011 pertussis outbreak in California, examined 10- to 17-year-olds who received the recommended four pertussis-containing vaccines. The researchers evaluated the risk of pertussis during the outbreak according to the number of whole-cell and/or acellular pertussis vaccines these participants had received as infants and toddlers.

Despite high levels of vaccine coverage, pertussis epidemics have arisen every three to five years since the 1980s, with progressively higher incidence rates over time. "Studies have suggested that protection following the acellular pertussis vaccine is less enduring than following the whole-cell pertussis vaccine," said lead author Nicola Klein, MD, PhD, co-director of the Kaiser Permanente Vaccine Study Center and a pediatrician. "Although reasons for the recurrent pertussis outbreaks are complex, waning protection following five doses of acellular pertussis vaccine plays a central role, at least in recent epidemics."

The study included 138 individuals with confirmed pertussis, 899 individuals who had a lab test indicating they did not have pertussis, and 54,339 individuals who were similar to those with confirmed pertussis on sex, race/ethnicity, medical clinic and membership status.

Increased number of acellular doses from zero to four was significantly associated with an increasing percent of positive pertussis tests. On average, individuals had a 40 percent increased risk of pertussis for each additional acellular dose received (as compared to receipt of a DTwP dose) between ages 1-24 months.

Teenagers who were vaccinated with four doses of acellular vaccines were at almost six times higher risk of pertussis than were those who had received four doses of whole-cell vaccines. Persons who received mixed whole-cell and acellular vaccines had an intermediate level of risk between those who received all whole-cell or all acellular vaccines. Those who received mixed vaccines were at nearly four times higher risk of pertussis than were those who received all whole-cell vaccines.

Earlier studies by Kaiser Permanente have shown that protection from the fifth dose of acellular pertussis vaccine wanes substantially during the five years after vaccination among children 4 to 12 years of age who have only received the acellular vaccine. The current study included only individuals born in 1999 or earlier, for whom at least five years had passed since receipt of the fifth pertussis vaccine.

Since 2005, the Advisory Committee on Immunization Practices has recommended boosting with reduced antigen content acellular pertussis vaccine, also known as Tdap, for persons 11 years and older. The study found that a booster dose of Tdap did not overcome the advantage in protection from pertussis seen among those who had received four doses of the whole-cell vaccine.

"The results indicate that a booster dose of Tdap does not overcome the advantage in protection from pertussis afforded to those who previously received four doses of the whole-cell vaccine," Dr. Klein said. "Despite this, boosting the newly emerging cohort of acellular pertussis vaccine-only teenagers with Tdap remains the best means currently available to help protect this group against disease."

Studies demonstrate that whole-cell and acellular pertussis vaccines administered to infants trigger different immune responses that at least partially persist through the teenage years, but long-term clinical consequences of such differences have been unknown. The results of this study, the researchers said, suggest that variations in immune responses induced by primary immunization during infancy play a central role in protection from disease years later. Additionally, the study highlights the need for new pertussis vaccines that provide both an improved safety profile and long lasting immunity.

Read more...
OrbusNeich obtains additional preliminary injunction against Boston Scientific in Germany (15.05.2013)
OrbusNeich Medical Inc. and its subsidiary, OrbusNeich Medical GmbH (collectively, "OrbusNeich"), today announced that the Dusseldorf Regional Court has issued a second preliminary injunction against the importation, distribution, sales and marketing of certain stent systems by Boston Scientific in Germany.
 
 This preliminary injunction was issued ex-parte against two companies – Boston Scientific (UK) Ltd. and Boston Scientific Ltd. – that Boston Scientific was using to intentionally circumvent a prior order of the Court banning sales of the same stent systems in Germany by other entities in the Boston Scientific corporate group.

On April 30, 2013, the Regional Court issued a preliminary injunction against U.S.-based Boston Scientific Corporation (NYSE: BSX) and its German subsidiary Boston Scientific Medizintechnik GmbH, prohibiting the importation, distribution, sales and marketing in Germany of the Small Vessel, Small Workhorse and Workhorse Stents of Boston Scientific's PROMUS Element™, PROMUS Element Plus™, OMEGA™, TAXUS Element™, SYNERGY™ and Promus PREMIER™ product lines.  In its April 30 decision, which Boston Scientific has appealed, the Regional Court found that the geometric pattern of these stents infringe OrbusNeich's patent EP 1 341 482.  As previously announced, OrbusNeich enforced the injunction on May 7, 2013. From that date forward, Boston Scientific Corporation and its German subsidiary were prohibited from taking any further actions that would infringe the '482 patent in Germany.

Rather than respecting the injunction, Boston Scientific immediately took steps to circumvent it.  Boston Scientific transferred the German distribution of these products to Boston Scientific (UK) Ltd. and Boston Scientific Ltd.  The company then sent a letter to its German customers advising them of the injunction and announcing that infringing products could be ordered from Boston Scientific UK.  The letter provided contact information for orders and assured customers that a German-speaking salesperson would be at their disposal.  These acts prompted the filing of the second preliminary injunction request, which was granted yesterday and which Boston Scientific may appeal.  OrbusNeich has immediately initiated enforcement of this new preliminary injunction.

"If Boston Scientific keeps shifting distribution to other entities, we will continue to seek further injunctions and any other penalties available under German law," said Al Novak, Chairman and Chief Executive Officer of OrbusNeich. "Further to this second preliminary injunction, we have also filed a request that the Regional Court penalize Boston Scientific for the recent violations of the Court's order."    

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous™ Stent, as well as other stents and balloons marketed under the names of Azule™, R stent™, Scoreflex™, Sapphire™, Sapphire II™ and Sapphire NC™. Development stage products include the COMBO Dual Therapy Stent™, the world's first dual therapy stent. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. 
Read more...
Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327 (13.05.2013)
Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients. CT327 is a novel, topical, TrkA kinase inhibitor developed using Creabilis' LSE (Low Systemic Exposure) technology that creates 'topical-by-design' drugs.

Chronic pruritus is a debilitating symptom of many dermatological diseases and has a significant impact on quality of life, including sleep. It is the cardinal symptom in atopic dermatitis and a key symptom of psoriasis. No medicine is currently approved for chronic pruritus.

Patients receiving CT327 showed a statistically significant and clinically meaningful reduction in pruritus compared to blinded placebo vehicle. Pruritus was measured using a visual analogue scale (VAS), the accepted regulatory endpoint. The reduction from baseline in pruritus VAS reached 60% for CT327 compared to 20% for vehicle alone (p<0.05). A clinically meaningful reduction in pruritus (VAS ≥ 20mm) was seen in up to 79% of patients for CT327 compared to 36% for vehicle alone (p<0.05).  At baseline, 69% of patients reported at least moderate pruritus (VAS > 40mm).

An improvement was also seen in the CT327 treated groups versus vehicle in mPASI (modified Psoriasis Area and Severity Index) in all patients. In patients with at least moderate pruritus at the start of the trial, significant reductions in mPASI were observed for CT327 compared to vehicle.  There was no significant impact of any dose of CT327 on the IGA (Investigator Global Assessment) endpoint.

CT327 was safe and well tolerated with no site application reactions and no systemic exposure. Notably, patients on CT327 reported fewer adverse events and withdrawals due to pruritus than the vehicle treated patients.

Eliot Forster, CEO of Creabilis, said: "We are excited by the results seen in this Phase 2b trial. In particular, the benefits of CT327 in treating pruritus are very encouraging and take us closer to the market in an indication with no currently available treatments. We anticipate further clinical development activity, targeting pruritus, in the near term. CT327 will represent a breakthrough for patients and doctors alike, both of whom currently struggle to deal with this distressing condition."  

David Roblin, CMO of Creabilis, said: "Pruritus is a debilitating yet under-recognised symptom in psoriasis and in other dermatological and systemic diseases. It has a significant impact on patients' quality of life and is currently poorly treated. There are no licensed products available, nor an established standard of care. There is a significant unmet need for a targeted treatment of chronic pruritus that combines efficacy with a good safety profile. In this study, up to 77% of CT327 treated patients had no or mild pruritus by the end of therapy. Combined with its outstanding safety profile, CT327 has the potential to provide a great benefit to patients."

About the Trial

The trial was a randomised, double-blind placebo controlled dose finding study of the efficacy and safety of a CT327 ointment at 0.05%, 0.1% and 0.5% w/w administered twice daily for eight weeks. One hundred and sixty patients with mild to moderate psoriasis were recruited. The study endpoints were IGA (Investigator Global Assessment), pruritus (VAS), mPASI and adverse event reports. Full data are expected to be presented at a scientific meeting later in 2013.

About Creabilis SA

Creabilis is a late clinical stage European biotechnology company with corporate and R&D functions spread across the UK and Italy.

Creabilis' primary focus is in chronic pruritus, a debilitating symptom of many dermatological diseases with a negative impact on quality of life. Chronic pruritus is an area of significant unmet need, with no medicine currently approved for its treatment.

Creabilis has delivered positive Phase 2b results for CT327 in the treatment of pruritus in psoriasis patients. CT327 is a novel, first-in-class, topically delivered TrkA kinase inhibitor. CT327 was developed using Creabilis' proprietary Low Systemic Exposure (LSE) 'topical-by-design' technology. LSE creates molecules optimized for topical applications. Planning for Phase 3 with CT327 is underway, with a clear route to market and an estimated >$800m in peak annual sales.

Creabilis' pipeline also includes CT340, a potent narrow spectrum kinase inhibitor in development for the topical treatment of neuropathic pain, an area of significant unmet medical need. Like CT327, CT340 was developed using the Company's Low Systemic Exposure (LSE) technology. CT340 is IND-ready and first-in-human studies will commence in 2013.

Creabilis is backed by highly respected life science investors Sofinnova Partners, Neomed and AbbVie Biotech Ventures Inc., and is led by an experienced Management team, with over 100 years of combined R&D experience in pharma and biotech, and over 20 drug approvals.

Read more...

Medical Fair Thailand 2013 by Messe Dusseldorf Asia Pte Ltd3


Hospital Build & Infrastructure Europe 2013
E-newsletter - latest issue of Hospital & Healthcare Management Magazine
To view this email as a web page, go here.
Hospital&Healthcare Management

Knowledge Partner:
HIMSS AsiaPac Logo

Newsletter - our this issue encompasses vital information on....
ARTICLES - Click here for more Articles
The Opportunity Wave is Hitting Healthcare: Surf’s Up!
The underlying principle behind the inability of any health system to offer all medical services, to everyone, right now and all the time, has to do with the fundamental driver of all...
 
Singapore’s Journey to Build a National Electronic Health Record System
As other countries continue to grapple with the issue of how to implement a nationwide electronic health record, Singapore’s Ministry of Health (MOH) has embarked on its journey to build a ...
 
Interview: Mr. Rajendra Pratap Gupta on Hospital Informatics in India.
Rajendra Pratap Gupta Speaks on Question 1: Which are the areas the hospitals must implement the informatics to increase their operational efficiency?...
 
Consumers Connect Health Monitors to Online Sites
Consumers are logging on to Web Sites with heart and blood monitors and sleep trackers to understand and improve their health.Growing numbers of health-conscious consumers are connecting themselves to Web-based health services.....
 
Case Study: Healthcare Provider Prescribes Integrated Portal to Boost Productivity, Quality of Care
St. Joseph Health System was early in giving its physicians online access to basic patient information. But as its doctors came to expect easy access to medical content, applications, and electronic medical records, St. Joseph Health System needed a broader solution....
 
Is eHealth enough to satisfy patients’ desire for self-service?
Patients wanting more self-service options for their healthcare. - Accenture survey show that patients embrace technology, but still want face-time with doctors. ...
 
Accountable care: Redefining value and success in healthcare
Today’s healthcare industry is undergoing a major change: The transformation to an accountable care model.Governmental, payer and industry bodies have all proposed healthcare quality measures designed to improve patient outcomes.....
 
Press Release - Global Perspectives on Health IT from Harvard Medical School Thought Leader
The HIMSS AsiaPac12(www.himssasiapac.org/) Conference and Exhibition in Singapore will begin with a keynote address by Dr. Blackford Middleton, Corporate Director, Clinical Informatics Research & Development, ...
 
PUBLICATION
Discussing about eHealth & Informatics have never been more important earlier.

With this in mind, we introduce the latest edition of Hospital & Healthcare Management your one-stop resource that hepls you stay up to date with the issues that matters ........
 
View Previous Issues:
April 2012 | December 2011 | August 2011
UPCOMING EVENTS - Click for more
September 2012
Medical Fair Asia 2012
12 – 14 Sep, 2012
Suntec, Singapore
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.medicalfair-asia.com


HIMSS Asiapac 2012
17-19 Sep, 2012
Marina Bay Sands, Singapore
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.himssasiapac.org

MedHealth & Wellness 2012

25 - 27 Sep, 2012
Oman International Exhibition Centre, Muscat
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.omanexpo.com/events.php

Health Facilities Infrastructure Saudi Arabia
30 Sep - 02 Oct, 2012
Radisson Blue, Riyadh, Saudi Arabia
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.healthfacilitiessaudi.com

October 2012
Health Informatics India Summit 2012
04 - 05 Oct, 2012
Hotel Le Meridien, New Delhi, India
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.healthinformaticsindia.com

Health Informatics and Leadership
06 - 09 Oct, 2012
Riyadh Marriott Hotel, Riyadh, Saudi Arabia
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.healthinformaticssaudi.com

5th Annual Middle East Healthcare Expansion Summit
10 - 11 Oct, 2012
Abu Dhabi, UAE
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.fleminggulf.com

Workforce Efficiency in Healthcare 2012
31 Oct - 01 Nov, 2012
Bayview Eden, Melbourne, Australia
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.healthcareworkforce.com.au

December 2012
mHealth Summit 2012
03 - 05 Dec, 2012
Gaylord National Resort & Convention Center, Washington DC, USA
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.mhealthsummit.org

Hospital Build & Infrastructure India
14 - 16 Dec, 2012
Bombay Exhibition Centre, Mumbai, India
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.hospitalinfra-india.com

April 2013
MEDEXPO Saudi Arabia 2013
02 - 04 Apr, 2013
Jeddah Center for Forums & Events, Jeddah, Kingdom of Saudi Arabia
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.medexposaudi.com

16th Southeast Asian Healthcare & Pharma Show 2013
24 - 26 Apr, 2013
Kuala Lumpur Convention Centre, Malaysia
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.abcex.com

CONTACT DETAILS

Please feel free to contact:
Support Department
M: +91 8447612124
E: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
W: www.hhmglobal.com

Merge Reports Second Quarter Sales Growth of 13%

 Merge Healthcare Incorporated (Nasdaq:MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, today announced its financial and business results for the second quarter of 2012. "Our second quar...
More:

Mirada Medical supplies deformable fusion technology study at ASTRO

Mirada Medical has integrated its multi-modal Deformable Fusion technology into Varian's SmartAdapt application and will present a study assessing the efficacy of the technology for MR to CT deformable registration at the annual meeting of the Am...
More:

A new simple blood test shows promise for improving diagnosis and clinical management of pre-eclamp

An editorial published this week in the Lancet online1 highlights the shocking fact that many maternal deaths in the UK are associated with substandard care and are potentially preventable. According to the latest report of Confidential Enquires into...
More:

IMI Builds Collaborations to Monitor Vaccine Safety and Drug Effectiveness

The Innovative Medicines Initiative (IMI) is calling experts to join forces and tackle two challenges which are of major importance to public health. Measuring the combined benefits and risks of vaccines and assessing the effectiveness of new medicat...
More:

Up Coming Webinars

webners Register through HHM Global for the upcoming webinars conducted by the leading providers covering subjects on various spectrums within the healthcare industry:

  • OCT: Does It Have What It Takes to Move Beyond its Commercial Tipping Point? - Frost & Sullivan
  • Creating a IT Client Infrastructure (VDI) that Optimizes the Clinician Experience - Lessons of an Early Adopter - HIMSS
  • eCare Communities or Healthcare Information Exchanges: What Are We Really Trying to Build? - HIMSS
16th Southeast Asian Healthcare and Pharma Show 2013
SUBSCRIPTION
Subscribe for E-Newsletter

Publication

hospital-and-healthcare-management-magazineFeb. 2013 - view e-book

Discussing about healthcare facilities & customer's benefit have never been more important earlier.

With this in mind, we introduce the latest edition of Hospital & Healthcare Management - Vol 3 Issue 1 your one-stop resource that hepls you stay up to date with the issues that matters most.

View Previous Issues:
Aug. 2012 | April 2012 | Dec. 2011 | Aug. 2011 | Issues 

Product Showcase

 

Flowline Worlds only Servo controlled High Frequency Oscillatory Ventilator DRAGONFLY

WORLDS Only SERVO Controlled High Frequency Oscillatory Ventilator (HFOV) Model DRAGONFLY Features: ...

 

Siemens Introduces Women s Imaging Premium Ultrasound Platform

Siemens Healthcare introduces the Acuson S2000 ultrasound system – Women’s Imaging at th...
Advertisement

Feedback Form
Real Time Web Analytics